-46.14
80,242.24
-0.06%
Market Closed
-46.14
80242.24
-0.06%
Market Closed

CRR_Call Tracker

Text/HTML

Text/HTML

ValueProductView

ValueProductPastPerformance

Company NameReco DateReco PriceExit PriceExit Date% ReturnIn days
Bharat Forge Ltd. 25/07/20241,593.85952.3007/04/2025 -40.25% 256 days
ITC Ltd. 28/12/2023464.20487.5002/01/2025 5.02% 1 yrs
Britannia Industries Ltd. 27/07/20234,875.805,028.2512/11/2024 3.13% 1 yrs
JSW Steel Ltd. 22/02/2024826.951,003.0026/09/2024 21.29% 217 days
Bajaj Auto Ltd. 22/08/20249,910.0011,930.0017/09/2024 20.38% 26 days
Dr. Reddy's Laboratories Ltd. 26/10/20235,429.306,536.0005/07/2024 20.38% 253 days
Shriram Finance Ltd. 25/04/20242,430.102,955.0028/06/2024 21.60% 64 days
Coal India Ltd. 25/01/2024389.50501.6022/05/2024 28.78% 118 days
Infosys Ltd. 27/10/20221,522.601,411.6019/04/2024 -7.29% 1 yrs
State Bank Of India 25/05/2023581.30782.0505/03/2024 34.53% 285 days

CRR_MVC_PastPerformance

Text/HTML

Our Other Trader Products

EasyDNNNews

Lupin launches generic version of Vimovo in US
DSIJ Intelligence
/ Categories: Trending, DSIJ News

Lupin launches generic version of Vimovo in US

Pharma major Lupin Limited announced the launch of an authorised generic version of Horizon Therapeutics PLC's Vimovo delayed action release tablets, 375 mg/20 mg and 500 mg/ 20 mg in the US.

The drug is a combination of Naproxen, a Non-Steroidal Anti-Inflammatory Drug (NSAID) and esomeprazole magnesium, a Proton Pump Inhibitor (PPI) indicated in patients of 12 years of age and older, weighing at least 38 kg, who require Naproxen for symptomatic relief of Arthritis and esomeprazole magnesium to decrease the risk of developing Naproxen-associated gastric ulcers.

According to Quintiles and IMS Health (IQVIA) MAT January 2020, Naproxen and Esomeprazole Magnesium Delayed-Release Tablets or Vimovo, had an annual sale of around US$ 400 million in the US.

Lupin is an innovation-led transnational pharmaceutical company, headquartered in Mumbai (India). The company develops and commercialises a wide range of branded and generic formulations, biotechnology products and APIs in various markets.

At 9.20 am on Friday, the stock was trading at Rs 662.20, down by 2.10 per cent or Rs 14.20 per share. The 52-week high is recorded at Rs 882.15 and the 52-week low is Rs 621 on BSE.

Previous Article Performance perspective of Indian Equity Market
Next Article Stocks with buying interest
Print
1506 Rate this article:
4.0
Please login or register to post comments.

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR